Brought to you by 
UroGen Pharma, Ltd.
https://www.urogen.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UroGen Pharma, Ltd.
Biotechs Face Daunting Launch Environment Going It Alone
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.
Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer
Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Biomaterials